Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

25
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
25
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

30
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
30
Prodrugs01:30

Prodrugs

4.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient.

Scientific reports·2020
Same author

Prevalence of Vitamin D Deficiency in a Large Newborn Cohort from Northern United States and Effect of Intrauterine Drug Exposure.

Nutrients·2020
Same author

DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype.

Current genomics·2020
Same author

Diagnostic performance of EUS in non-jaundiced patients with an incidental finding of double duct sign on cross-sectional imaging: A systematic review and meta-analysis.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2020
Same author

Giant Liver Hemangiomas: A Plea for Early Surgical Referral and Resection.

Case reports in surgery·2020
Same author

DeconPeaker, a Deconvolution Model to Identify Cell Types Based on Chromatin Accessibility in ATAC-Seq Data of Mixture Samples.

Frontiers in genetics·2020

Related Experiment Video

Updated: Feb 20, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K

Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics.

Min Hee Lee1, Amit Sharma, Min Jung Chang

  • 1Department of Chemistry, Sookmyung Women's University, Seoul 04310, Korea. minheelee@sookmyung.ac.kr.

Chemical Society Reviews
|October 24, 2017
PubMed
Summary

Theranostic systems combine cancer therapy and imaging for personalized medicine. Fluorogenic reaction-based conjugates offer targeted drug delivery and monitoring, improving cancer diagnosis and treatment.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K

Related Experiment Videos

Last Updated: Feb 20, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Theranostic systems integrate therapeutic and diagnostic capabilities.
  • Personalized medicine relies on accurate cancer diagnosis, staging, and treatment.
  • Targeted drug delivery enhances therapeutic efficacy and reduces side effects.

Purpose of the Study:

  • To introduce theranostic drug delivery systems using targeted conjugates.
  • To discuss design concepts for cancer-targeting theranostics.
  • To highlight fluorogenic reaction-based systems for enhanced cancer therapy and imaging.

Main Methods:

  • Synthesis of conjugates with imaging reporters, masked drugs, linkers, and targeting ligands.
  • Utilizing cellular entities (thiols, ROS, enzymes) and tumor microenvironment characteristics (hypoxia, pH) for activation.
  • Exploring external stimuli like light for system activation.

Main Results:

  • Demonstrated design principles for theranostic conjugates.
  • Highlighted the activation of imaging and therapeutic functions by tumor-specific conditions.
  • Showcased the potential of fluorogenic systems for in vitro and in vivo monitoring.

Conclusions:

  • Fluorogenic, cancer-targeting theranostics show promise for advancing drug discovery.
  • These systems improve understanding of cellular uptake and drug release mechanisms.
  • Theranostics are poised to significantly impact personalized cancer medicine.